AC Immune Stock

AC Immune EBIT

The EBIT of AC Immune (ACIU) as of Aug 15, 2026 is -52.38 M CHF. In the previous year, EBIT was -53.62 M CHF — a change of -2.32% (higher).

EBIT

-52.38 MCHF

YoY

-2.32%

Last updated:

In 2026, AC Immune's EBIT was -52.38 M CHF, a -2.32% increase from the -53.62 M CHF EBIT recorded in the previous year.

The AC Immune EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M CHF)
Date
EBIT (M CHF)
Jan 1, 2023
-53.62 base
Jan 1, 2024
-52.38 base
Jan 1, 2025 (e)
-2.60 base
Jan 1, 2026 (e)
-21.41 base
Jan 1, 2027 (e)
-51.80 base
Jan 1, 2028 (e)
-61.58 base
Jan 1, 2029 (e)
-41.94 base
Jan 1, 2030 (e)
-45.48 base
YEAREBIT (M CHF)
2030 est -45.48
2029 est -41.94
2028 est -61.58
2027 est -51.80
2026 est -21.41
2025 est -2.60
2024 -52.38
2023 -53.62
2022 -70.80
2021 -79.00
2020 -61.30
2019 44.50
2018 -49.60
2017 -22.50
2016 -10.50
2015 18.60
2014 10.70
2013 -11.50
Access this data via the Eulerpool API

AC Immune Revenue

AC Immune Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
14.80 M CHF
-53.62 M CHF
-54.23 M CHF
Jan 1, 2024
27.31 M CHF
-52.38 M CHF
-50.92 M CHF
Jan 1, 2025 (e)
4.34 M CHF
-2.60 M CHF
-60.20 M CHF
Jan 1, 2026 (e)
35.68 M CHF
-21.41 M CHF
-29.58 M CHF
Jan 1, 2027 (e)
86.33 M CHF
-51.80 M CHF
18.58 M CHF
Jan 1, 2028 (e)
102.63 M CHF
-61.58 M CHF
33.74 M CHF
Jan 1, 2029 (e)
69.89 M CHF
-41.94 M CHF
-2.79 M CHF
Jan 1, 2030 (e)
75.81 M CHF
-45.48 M CHF
-3.78 M CHF

AC Immune Margins

AC Immune stock margins

The AC Immune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AC Immune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AC Immune.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
0.00 %
-362.30 %
-366.41 %
Jan 1, 2024
0.00 %
-191.80 %
-186.44 %
Jan 1, 2025 (e)
0.00 %
-60.00 %
-1,387.46 %
Jan 1, 2026 (e)
0.00 %
-60.00 %
-82.89 %
Jan 1, 2027 (e)
0.00 %
-60.00 %
21.53 %
Jan 1, 2028 (e)
0.00 %
-60.00 %
32.88 %
Jan 1, 2029 (e)
0.00 %
-60.00 %
-3.99 %
Jan 1, 2030 (e)
0.00 %
-60.00 %
-4.98 %

AC Immune Stock analysis

What does AC Immune do? AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing AC Immune's EBIT

AC Immune's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of AC Immune's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

AC Immune's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in AC Immune’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about AC Immune stock

EBIT of AC Immune is -52.38 M CHF in 2026.

EBIT of AC Immune changed from -53.62 M CHF to -52.38 M CHF, representing a -2.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT AC Immune since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's AC Immune historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — AC Immune

All Key Metrics — AC Immune